儿茶酚胺与非儿茶酚胺血管升压药对血管舒张性休克肾功能及恢复的影响:临床前与临床研究的系统评价
该系统评价检索MEDLINE、Embase和Cochrane Central,纳入90项研究(41项临床前、17项非随机临床、28项随机临床、4项事后分析),比较儿茶酚胺类(去甲肾上腺素、肾上腺素、间羟胺、去氧肾上腺素、多巴胺)与非儿茶酚胺类(血管加压素、血管紧张素II)血管升压药对血管舒张性休克中急性肾损伤风险与恢复的影响。临床前研究显示儿茶酚胺加重髓质缺氧和肾内炎症;临床研究显示儿茶酚胺与更高的血清肌酐、更低的尿量和增加的肾脏替代治疗需求相关;在接受高剂量儿茶酚胺的患者中,辅助性血管紧张素II与改善肾脏替代治疗脱离相关。作者结论认为非儿茶酚胺类血管升压药可能带来肾脏获益,这些观察属假说生成性,提示需要以肾脏结局为目标的对比研究。
要点
- 临床研究显示,与非儿茶酚胺类血管升压药相比,儿茶酚胺类与更高的血清肌酐、更低的尿量和增加的肾脏替代治疗需求相关。
- 临床前研究显示,与非儿茶酚胺类相比,儿茶酚胺类血管升压药加重髓质缺氧和肾内炎症。
- 在接受高剂量儿茶酚胺的患者中,辅助性血管紧张素II与改善肾脏替代治疗脱离相关。
- 该系统评价共纳入90项研究:41项临床前研究、17项非随机临床研究、28项随机临床研究和4项事后分析。
- 作者结论认为,非儿茶酚胺类血管升压药可能带来肾脏获益,这些观察属假说生成性,提示需要以肾脏结局为目标的对比研究。
适用人群与场景
- 临床前模型或成人血管舒张性休克队列。
- 研究对象为报告儿茶酚胺类(去甲肾上腺素、肾上腺素、间羟胺、去氧肾上腺素、多巴胺)或非儿茶酚胺类(血管加压素、血管紧张素II)血管升压药相关肾脏结局的研究。
研究设计与关键结果
- 系统评价:检索MEDLINE、Embase和Cochrane Central Register of Controlled Trials,从3504条引文中共纳入90项研究:41项临床前研究、17项非随机临床研究、28项随机临床研究和4项事后分析。
- 偏倚风险:临床前研究普遍为低,临床研究为低至中等。
- 临床前研究:与非儿茶酚胺类血管升压药相比,儿茶酚胺类血管升压药加重髓质缺氧和肾内炎症。
- 临床研究:与非儿茶酚胺类血管升压药相比,儿茶酚胺类与更高的血清肌酐、更低的尿量和增加的肾脏替代治疗需求相关。
- 在接受高剂量儿茶酚胺的患者中,辅助性血管紧张素II与改善肾脏替代治疗脱离相关。
- 作者结论:临床前与临床研究提示,与非儿茶酚胺类血管升压药相比,非儿茶酚胺类血管升压药可能带来肾脏获益;这些观察属假说生成性,提示需要以肾脏结局为目标的对比研究。
证据类型、等级与局限
- 证据类型:系统评价,纳入临床前研究、非随机临床研究、随机临床研究和事后分析。
- 偏倚风险:临床前研究普遍为低,临床研究为低至中等。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,临床前与临床研究提示非儿茶酚胺类血管升压药可能相较儿茶酚胺类带来肾脏获益,但这些观察属假说生成性,提示需要以肾脏结局为目标的对比研究。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Background: Acute kidney injury (AKI) is a common complication of vasodilatory shock. AKI is associated with an increased risk of death, prolonged hospital stays, and subsequent transition to chronic kidney disease. Catecholamines have historically been used as the first-line vasopressors for vasodilatory shock; however, they may adversely affect renal function and recovery. Objectives: To compare the effects of catecholamine and noncatecholamine vasopressors on AKI risk and recovery in preclinical and clinical studies of vasodilatory shock. Methods: MEDLINE, Embase, and Cochrane Central Register of Controlled Trials were systematically searched to identify studies reporting renal outcomes associated with catecholamine (norepinephrine, epinephrine, metaraminol, phenylephrine, dopamine) and noncatecholamine vasopressors (vasopressin, angiotensin II), in preclinical models or adult cohorts of vasodilatory shock. Two independent reviewers screened studies and extracted data using a prespecified form for qualitative synthesis and risk of bias assessment. Results: Of 3,504 citations, 90 studies were eligible for inclusion: 41 preclinical studies, 17 nonrandomized clinical studies, 28 randomized clinical studies, and 4 post-hoc analyses. Risk of bias was generally low in preclinical studies and low to moderate in clinical studies. In preclinical studies, catecholamine vasopressors exacerbated medullary hypoxia and intrarenal inflammation compared to noncatecholamine vasopressors. In clinical studies, catecholamines were associated with higher serum creatinine, lower urine output, and increased requirements for renal replacement therapy compared to noncatecholamine vasopressors. In patients on high-dose catecholamines, adjunctive angiotensin II was associated with improved renal replacement therapy liberation. Conclusion: Preclinical and clinical studies suggest that noncatecholamine vasopressors may confer renal benefits compared to catecholamine vasopressors. These hypothesis-generating observations suggest the need for comparative studies focused on renal outcomes. Systematic Review Registration : PROSPERO 2024 CRD42024527773.
参考来源
- Vernon-Elliot J, Goradia S, Bellomo R, et al. THE EFFECT OF CATECHOLAMINE VERSUS NONCATECHOLAMINE VASOPRESSORS ON RENAL FUNCTION AND RECOVERY IN VASODILATORY SHOCK: A SYSTEMATIC REVIEW OF PRECLINICAL AND CLINICAL STUDIES. Shock. 2024. PMID: 39617403. doi:10.1097/SHK.0000000000002515
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。